The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis

Pregnancy Related Clinical Trial

Official title: The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis

Status Terminated

Clinical Trial Summary

Pregnant women with a history of opioid use disorder, chronic opioid use or those who are on medication assisted treatment will be randomly assigned to receive either a sub-fascial continuous infusion of bupivacaine or lidocaine/menthol patch after Cesarean delivery. Post-operative pain scores and opioid usage in the post-operative period will be recorded.

Clinical Trial Description

Pregnant women 18 years or older with a history of chronic opioid use, opioid use disorder or women on medication assisted treatment (MAT), will be enrolled in the study and randomly assigned to one of two study groups. The first group will receive a Lidocaine/Menthol patch at the time of her Cesarean delivery, the second will receive placement of the Ambu ACTion infusion pain system at the time of the C-section. This device will be set up to infuse 0.125% of bupivacaine for 48-60hrs postoperatively at a rate of 8cc/hr. ;

Related Conditions & MeSH terms

• Ambu ACTion
• Cesarean Section
• Infusion Catheter, Wound
• Lidopatch
• Medication Assisted Treatment
• Opioid Abuse
• Opioid Dependence
• Opioid Use
• Opioid-Related Disorders
• Opioid-use Disorder
• Pregnancy Related

• NCT number: NCT04033562
• Study type: Interventional
• Source: WellSpan Health
• Status: Terminated
• Phase: Phase 4
• Start date: January 15, 2020
• Completion date: May 17, 2021